We describe a comprehensive translational approach for identifying candidate genes for alcoholism. The approach relies on the cross-matching of animal model brain gene expression data with human genetic linkage data, as well as human tissue data and biological roles data, an approach termed convergent functional genomics. An analysis of three animal model paradigms, based on inbred alcohol-preferring (iP) and alcohol-nonpreferring (iNP) rats, and their response to treatments with alcohol, was used. A comprehensive analysis of microarray gene expression data from five key brain regions (frontal cortex, amygdala, caudate-putamen, nucleus accumbens and hippocampus) was carried out. The Bayesian-like integration of multiple independent lines of evidence, each by itself lacking sufficient discriminatory power, led to the identification of high probability candidate genes, pathways and mechanisms for alcoholism. These data reveal that alcohol has pleiotropic effects on multiple systems, which may explain the diverse neuropsychiatric and medical pathology in alcoholism. Some of the pathways identified suggest avenues for pharmacotherapy of alcoholism with existing agents, such as angiotensin-converting enzyme (ACE) inhibitors. Experiments we carried out in alcohol-preferring rats with an ACE inhibitor show a marked modulation of alcohol intake. Other pathways are new potential targets for drug development. The emergent overall picture is that physical and physiological robustness may permit alcohol-preferring individuals to withstand the aversive effects of alcohol. In conjunction with a higher reactivity to its rewarding effects, they may able to ingest enough of this nonspecific drug for a strong hedonic and addictive effect to occur.
Introduction
Alcoholism is a prevalent problem in the United States and across the world. During the course of their lives, approximately 10-13% of Americans are affected by alcohol dependence. 1 Alcohol dependence is a chronic relapsing disorder characterized by the inability to self-control drinking, tolerance to the effects of alcohol, characteristic withdrawal symptoms and negative personal as well as social consequences. [2] [3] [4] [5] Family, twin and adoption studies have shown that genetic factors contribute 40-70% of the risk for the development of alcoholism [6] [7] [8] [9] and exposure to alcohol has been shown to change gene expression patterns in the brains of both experimental animals and humans. 10, 11 Alcoholism is likely a polygenic, non-Mendelian disorder with variable penetrance and complex clinical phenotypes. As a result, with a few notable exceptions, [12] [13] [14] [15] [16] [17] [18] [19] [20] human genetic studies so far have had limited success in definitively identifying individual genes involved in the pathophysiology of alcoholism.
Convergent functional genomics (CFG) [21] [22] [23] [24] is an approach that aims to unravel the genetics of complex neuropsychiatric disorders, and has been applied with some success to bipolar and related disorders. 25 CFG integrates gene expression data from a relevant animal model with human genetic linkage data, as well as human tissue gene expression data (post-mortem brain, lymphocytes) and biological roles data, as a Bayesian way of cross-validating findings, reducing uncertainty and coming up with a short list of high probability candidate genes. Those genes can subsequently be followed up in a prioritized manner and studied on an individual basis, in mouse transgenic models and human candidate gene association studies, for definitive confirmation of their involvement in disease pathophysiology. In this study, we have applied our expanded CFG approach 24, 25 ( Figure 1 ) to identify candidate genes for alcoholism and related disorders.
Internal lines of evidence
The experimental approaches used to produce the animal model data for CFG analysis were carried out in two rat lines selectively bred for divergent alcohol preference; inbred alcohol-preferring (iP) vs inbred alcohol-non-preferring (iNP) rats. Five brain regions were chosen for gene expression studies in these rat lines: the frontal cortex (FC), amygdala (AMY), caudate-putamen (CP), nucleus accumbens (NAC) and hippocampus (HIP). Animal studies, human imaging and post-mortem analyses have previously provided evidence that these regions are implicated in alcoholism. [26] [27] [28] Data for the analysis came from studies of three experimental paradigms. Paradigm 1 29 examined basal level of gene expression in the brains of the alcohol-naïve iP and iNP lines of rats. This basal comparison was performed to determine innate differences between these two lines with a marked divergence in the willingness to consume alcohol. It is hypothesized that the innate differences in gene expression between the iP and iNP would involve some of the genes associated with an increased susceptibility for alcohol dependence. The second paradigm examined the effects of chronic 24-h free-choice alcohol consumption on gene expression in iP rats compared with alcohol-naïve iP rats. 10 This paradigm looked for gene expression changes in the brain associated with the direct influence of peripherally self-administered alcohol in the genetically susceptible rats. In the third paradigm, 30 iP rats were allowed to directly selfinfuse alcohol directly into the posterior ventral tegmental area (VTA), the originating area of the mesolimbic dopamine system. The advantage of this latter procedure is that it isolates the neurocircuitry involved in alcohol reinforcement, and eliminates the peripheral effects of alcohol. Following the establishment of alcohol self-administration into the posterior VTA, gene expression levels in target brain areas were measured and compared with P rats that received artificial cerebral spinal fluid (aCSF) infusions into the posterior VTA.
Recognizing that not all the genes that show alterations in expression in the individual paradigms are necessarily associated with alcoholism, we propose that genes that show changes in expression in more than one paradigm are more likely to be central to the pathophysiology of alcoholism and are higher probability candidate genes. We labeled those genes that had expression changes in all three paradigms in the same brain region, Category I genes. Category II genes showed changes in two paradigms in the same brain region (Category IIa genes were those that changed both in Paradigms 1 and 2, Category IIb genes changed both in Paradigms 1 and 3 and Category IIc genes were those that changed in both Paradigms 2 and 3). Category III genes changed in only one paradigm (Category III-1, III-2 and III-3 We also reasoned that genes that had expression changes in more than one of the brain regions have a higher probability of being positive findings compared to genes that changed in a single region, at the very least for reproducibility reasons, as the assaying of different brain regions are essentially independent experiments. Our approach of looking at the overlaps of three very different alcohol-related paradigms also has the virtue of factoring out, at least in part, gene expression changes that are potentially artifactual, related to the inbreeding process or to the experimental manipulations involved in each particular paradigm, and not to alcohol. This is a very important point, as inbred strains are vulnerable to the accumulation of a variety of aberrations at later generations. 31, 32 For these reasons, we are not focusing in this report on genes that are changed exclusively in a single paradigm of the three studied (Category III genes).
External lines of evidence
We used three external cross-validators in our expanded CFG analysis. 25 First, each gene was assessed to see if it mapped to a linkage locus that had been reported to be associated with alcoholism. Our criterion was mapping within 10 centimorgans (cM) of a marker that has shown significant evidence of linkage 21 to alcoholism, with a lod score 42 in at least one published study. We also looked more broadly at cross-matching with linkage data from other neuropsychiatric disorders (bipolar disorder, schizophrenia), based on the rationale that their clinical comorbidity with alcoholism may be due, at least in part, to genetic overlap. 33 Second, we searched to see if there was any human tissue data (post-mortem brain, lymphocytes, fibroblasts) showing expression changes of the gene in patients who had had alcoholism or, more broadly, other neuropsychiatric disorders (bipolar disorder, schizophrenia, major depression, anxiety, other substance dependence disorders, dementia, suicide). Third, we looked at the known biological functions associated with the gene and asked if it had any relevance to the pathophysiology of alcoholism and/or other neuropsychiatric disorders. Including disorders other than alcoholism in our external lines of evidence arguably dilutes the specificity of our approach. We nevertheless decided to include them as a way of increasing sensitivity, based on the emerging clinical, neurobiological and genetic evidence of substantial overlap between these disorders and alcoholism, 18, [33] [34] [35] [36] [37] and the likelihood that published alcohol-related data sets to date are non-exhaustive. To address the issue of specificity, we decided to weight differentially the significance of the association with alcoholism with a score of 1, and with any other neuropsychiatric disorder with a lesser score of 0.5.
Scoring the lines of evidence
Each gene in our data set was studied using four internal and three external lines of evidence ( Figure 2 ). For each paradigm, an empirical score of 1 was given for its contributory line of evidence (gene expression change) in the same brain region. As such, a Category I gene would receive 3 points, a Category II genes 2 points and a Category III gene 1 point. If a gene showed expression changes in multiple brain regions, 0.5 point was given for each paradigm in which it showed up as changed in other brain regions also. A maximum score of 4.5 can thus be generated by the four internal lines of evidence. For the external lines of evidence, a gene that mapped within 10 cM of a marker for alcoholism was given 1 point, and within 10 cM of a marker for another neuropsychiatric disorder, 0.5 point. Genes that had a biological function relevant to alcoholism received 1 point, and if their biological function was relevant to the pathophysiology of another neuropsychiatric disorder (bipolar disorder, schizophrenia, major depression, anxiety, other substance dependence disorders, dementia, suicide), 0.5 point. Last but not least, a gene that had published evidence of expression changes in human tissue data (post-mortem brains, lymphocytes, fibroblasts) from patients with a history of alcoholism was given 1 point, and for tissue data from another neuropsychiatric disorder, 0.5 point. The maximum score a gene could receive in any external line of evidence was set at 1.5 points. A maximum score of 4.5 can be generated by the external lines of evidence, like for the internal lines of evidence. Thus, totaling all the internal and external lines of evidence gives a maximum possible score of 9 points, with the internal evidence and the external evidence weighted equally.
It has not escaped our attention that different ways of scoring the independent lines of evidence could be used, which might give somewhat different results in terms of the prioritization of the top candidate genes, if not in terms of the actual content of the list per se. However, our simple weighted scoring is arguably a reasonable compromise between specificity and sensitivity, between focus and broadness.
Results
Number of genes A total of 3246 unique genes were changed with a Po0.05 in the three paradigms we used (Figure 1a ) (iP vs INP, chronic alcohol in iP, intracranial self-administration (ICSA) alcohol in iP), and in the five brain regions examined (FC, AMY, CP, NAC, HIP). In Paradigms 1 and 2, the highest number of genes changed was in the CP, followed by the AMY. In Paradigm 3, NAC had the highest number of gene changes, followed by AMY.
By using our internal convergence analysis (Figure 1b) , we narrowed the field to just four Category I genes (changed in all three paradigms -three independent lines of evidence) and 166 Category II genes (changed in at least two paradigms -two independent lines of evidence). The four genes changed in common in all three rat model experimental paradigms, two in the AMY (CD81, nucleoporin-like 1 (NUPL1)) and two in the CP (phosphatidylethanolaminebinding protein (PBP) and aldehyde dehydrogenase family 6, member A1 (ALDH6A1)) ( Table 1) . These regions are likely associated with the anxiolytic, respectively, the locomotor effects of alcohol.
Top findings
The genes in Categories I are shown in Table 1, and Category  II genes in Tables 2-4 . Our internal convergence analysis also included determining whether a gene is changed in multiple brain regions, which adds another internal line of evidence. The maximum score that a gene can get based on internal lines of evidence is 4.5. By then applying our external convergence analysis to all the genes in the data set, a maximum total score of 9 can be generated. Figure 3a summarizes in a pyramid format the assigned empirical probability scores based on the multiple internal and external lines of evidence, showing the 56 genes we identified that had a total score of 4 or greater. While the CP has the highest number of overall gene expression changes (Figure 2b) , it is interesting to note that the region with the highest average score per gene in the pyramid is the AMY, followed by the HIP, FC, NAC and lastly, CP ( Figure  3b ). This may speak to the more specific effects of alcohol on NAC ¼ nucleus accumbens; P ¼ inbred alcohol-preferring rats; NP ¼ inbred alcohol-non-preferring rats; SZ ¼ schizophrenia.
Fold-changes and P-values were calculated using Affymetrix Microarray Analysis Suite version 5.0 analysis software. All P-values were o0.05. Numbers with each brain region in the multiple brain regions column represent the paradigm in which the gene expression was changed. Genes with a line of evidence score of 4 or higher are shown.
anxiety (AMY), followed less specifically by its effects on memory formation (HIP), cognition (FC), hedonia (NAC) and lastly, locomotion (CP). At the top of our pyramid, we have 20 genes that show a score of greater than 4.5. This is of interest because this is the maximum score obtainable from internal lines of evidence alone, without any external confirmatory evidence. Six of these genes are from the AMY -fibronectin 1 (FN1) located at 2q35, CD81 located at 11p15.5, brain-derived neurotrophic factor (BDNF) located at 11p14.1, cyclin D1 (CCND1) located at 11q13.3, NUPL1 located at 13q12. 13 and protein kinase C epsilon (PRKCE) located at 2p21; four from the HIP -transferrin receptor (TFRC) located on 3q29, aldehyde dehydrogenase family 1, member A1 (ALDH1A1) on 9q21.2, 5-aminolevulinate synthase 1 (ALAS1) located on 3p21.2 and syntaxin 12-binding protein (STX12) at 1p35.3; four from the CP -synapsin II (SYN2) located at 3p25.2, mitogen-activated protein kinase 14 (MAPK14) at 6p21.31, neuritin 1 (NRN1) located at 6p25.1 and PBP located at 12q24.23; three from the NAC -vascular cell adhesion molecule 1 (VCAM1) located at 1p21.2, fyn oncogene (FYN) located at 6q21 and IGF1R located at 15q26.3; two from the FC -angiotensinogen (AGT) located at 1q42.2 and lysozyme (LYZ) located at 12q15; and one in multiple regionstyrosine hydroxylase (TH) located at 11p15.5.
Fibronectin 1
Notably, 14 of these top 20 genes are known to interact in a network with FN1 at its core ( Figure 4a ): VCAM1 38 and CD81 39 (cell adhesion and signaling), TFRC 40 and ALAS1
41
(iron-heme metabolism), AGT 42 and PRKCE 43 (cardiovascular regulation), insulin-like growth factor 1 receptor (IGF1R), 44 (synaptic transmission and neurite outgrowth). Moreover, several other genes in our data set, with a score of 4.5 or less, are part of FN1 pathways and interactions (neuronal cell adhesion molecule (NRCAM), PTK2B, RHOB, BCAR1). For a more complete view of all the known direct interactions between our top candidate genes, we have conducted a Pathways Assist analysis, as depicted in Figure 4b . This analysis also identified MAPK14 and AGT as key nodes in the interaction network. These genes will be discussed in more detail below.
As a caveat, it should be noted that most of the above inter-relationships were inferred from work in tissues other than the brain. However, it is reasonable to assume that similar inter-relationships might be functional in glial or neuronal populations. Other investigators have previously implicated a majority of the above-named genes, individually or as part of functional groups, in various biological and genetic contexts germane to the pathophysiology of alcoholism and related disorders, as discussed below. Our results, identifying these genes as top candidate genes, are thus a strong validation of the heuristic value and internal consistency of the approach we have used. Moreover, they outline networks of potentially co-acting genes, and support an important role for FN1 pathway in alcoholism and related disorders.
FN1 has previously been implicated in the myocardial fibrosis induced by chronic alcohol, 51 acute lung injury susceptibility induced by alcohol 46 as well as in cirrhosis of the liver. 52, 53 FN1 expression was also changed, in tissue culture, in glial cells treated with alcohol. 54 This suggests that perhaps a fibrosis-type process may underlie detrimental changes in the brains of alcoholics -a cirrhosis of sorts in the brain. Our data show that alcohol-preferring rats (iP), which are better able to withstand the intoxicating effects of alcohol, have lower baseline level of FN1 than alcohol-nonpreferring (iNP) rats, in multiple brain regions ( Table 2 ). iP rats are less susceptible to the motor-impairing effects of alcohol than iNP rats. 55 Additionally in iP rats, chronic alcohol consumption alters the sensitivity of the posterior VTA (lower concentrations of alcohol are self-administered) and increases the tolerance to the reinforcing properties of higher concentrations of alcohol (higher concentrations of alcohol are self-administered in chronically drinking iP rats than alcohol-naïve iP rats). 10, 30 Therefore, there appears to be an innate ability to withstand the intoxicating effects of alcohol in iP rats, and perhaps a genetic predisposition to develop further tolerance to the effects of alcohol. FN1 maps to a locus on 2q35 identified in a genome-wide screen for alcohol susceptibility genes. 56 That chromosomal location was also identified as linked to a cognitive trait component (visual working memory) in schizophrenia. 57 Interestingly, FN1 content was reported to be altered in fibroblasts from schizophrenia patients. 58 Moreover, FN1 gene expression was reported to be altered in post-mortem brains of human alcoholics. 59 Cell adhesion signaling and alcoholism Besides FN1, other molecules involved in cell adhesion signaling were among our top candidate genes.
CD81, a member of the tetraspanin superfamily of proteins, has been linked to a number of biologic functions, including cellular proliferation, differentiation, activation and degranulation. Mice lacking CD81 have been shown to have increased brain size and glial cell number.
60 CD81 seems to be important for neuronaly induced glial cell proliferation arrest. 61 CD81 is increased in the NAC by cocaine administration, and has been shown to mediate some of the behavioral activating effects of cocaine. [62] [63] [64] Our data show that CD81 is a Category I gene, changed in expression in the AMY in all three alcohol-related experimental paradigms we studied. While there seems to be an increase in the expression of CD81 in alcohol-preferring rats at baseline, of note there is a strong decrease in its expression in the NAC following ICSA administration of alcohol in the VTA (Table 1) , opposite to the effects of systemic administration of cocaine. This elevation of CD81 in the NAC of iP rats vs iNP rats, similar to the effects of cocaine in wild-type animals, suggests they may have a higher hedonic activity at baseline. Alternately, the level of CD81 in iP rats may have to do with the ability of the alcohol-preferring rats to withstand the aversive (sedative Convergent functional genomics of alcoholism ZA Rodd et al and intoxicating) effects of alcohol, and its decreased expression following alcohol administration may be a manifestation of those effects. The effects of alcohol in decreasing CD81 may be particularly relevant to brain development and glial proliferation during fetal alcohol syndrome. CD81 maps to a locus on 11p15.5 that has been linked to alcohol dependence by a genome-wide study in an American Indian population. 65 That locus also shows evidence for linkage to bipolar disorder 66 and schizophrenia. 67 VCAM1, involved in endothelial adhesion and migration of leukocytes, has previously been shown to be deficient in central nervous system (CNS) injury response in adult rats who had been exposed to alcohol in utero. 68 This suggests that neuroimmunomodulatory responses to tissue injury might be altered in alcoholics. VCAM1 has also been shown to be upregulated by another drug of abuse, cocaine, 69 probably through a noradrenergic mechanism. 70 Our data show that alcohol-preferring rats have higher baseline level of VCAM1 than alcohol-non-preferring rats in the NAC, and those levels are decreased by ICSA administration of alcohol directly in the VTA (Table 3) , opposite to the effects of systemic administration of cocaine. VCAM1 maps to a locus on 1p21.2 that shows linkage not only to alcoholism, in multiple studies, [71] [72] [73] [74] but also to bipolar disorder 67 and schizophrenia. 75 Last but not least, VCAM1 was reported to be upregulated in human post-mortem brains of patients with depression. 76 Taken together, these data on cell adhesion molecules, and the apparent opposite effects of cocaine and alcohol on them, support the possibility of them having a role more in withstanding the aversive effects of alcohol rather than in hedonic effects. These data also have interesting implications for the effect of alcohol on brain infrastructure, and the neurobiological and clinical overlap with bipolar disorder and schizophrenia. Moreover, at baseline the iP rats have a molecular profile that resembles the effects of cocaine administration in wild-type rats, and which translates phenotypically in increased locomotor behavior. 77 iP rats may also be particularly susceptible to the effects of cocaine and other stimulant drugs, 78 which mimics the human condition, where alcoholics are often polysubstance abusers. 79 Specifically, P rats self-administer cocaine directly into the accumbens shell at a greater than twofold lower concentration compared to Wistar rats. 30 In addition, P rats develop sensitization to cocaine-induced locomotor stimulation more readily than Wistar and iNP rats. 77 An opposite example to this paradigm is provided by another candidate gene in our data set, NRCAM, which has a role in cell adhesion and a role in the response to drug of abuse. NRCAM knockout mice display reduced opiate-and stimulant-conditioned place preferences. 80 NRCAM is not higher at baseline in iP rats than in iNP rats, but is increased by alcohol treatment in the CP, in our data set, in two independent paradigms (Table 4) . It maps to a locus on 7q31.1 implicated in alcohol dependence in the context of major depression.
14 Given the similarity of response of NRCAM to very different drugs (opiates, stimulants, alcohol), its role may have to do with the common hedonic effects of various drugs of abuse.
Iron-heme metabolism and alcoholism Among our top candidate genes, we have two genes involved in iron-heme metabolism, TFRC and ALAS1. Alcoholism is associated with an increased risk for cancers. Accumulation of iron and associated oxidative stress may contribute to this risk. 81 Carbohydrate-deficient transferrin has been established clinically as a biomarker of alcohol abuse, providing a reliable estimate of long-term alcohol intake. 82 TFRC expression is upregulated in hepatocytes by habitual alcohol drinking, and is implicated in hepatic iron overload in alcoholic liver disease. 83 Our data show that alcohol-preferring rats have a higher baseline level of TFRC than alcohol-non-preferring rats in the HIP, and that those levels are increased by the administration of alcohol (Table  2) . TFRC maps to a locus on 3q29 that has been implicated in alcoholism, 84 as well as in bipolar disorder and schizophrenia. [85] [86] [87] Moreover, TFRC gene expression was reported to be altered in post-mortem brains of human alcoholics.
88
ALAS1 is involved in the coordinated upregulation of apoprotein and heme synthesis in response to exogenous and endogenous signals controlling heme levels. 89 ALAS1 is upregulated in the liver and in peripheral blood cells in response to alcohol. 90 Interestingly, the circadian clock and heme biosynthesis are reciprocally regulated through ALAS1. 91 Our data show that alcohol-preferring rats have a higher baseline level of ALAS1 than alcohol-non-preferring rats in the HIP and that those levels are increased by administration of alcohol (Table 3 ). It would be of interest to study whether ALAS1 levels may mediate some of the circadian rhythm abnormalities associated with alcoholism.
92 ALAS1 maps to a locus on 3p21.2 that has been implicated in alcoholism, 74 as well as schizophrenia. 67 The importation of iron into cells by TFRC and heme synthesis by ALAS1 may serve, in moderation, a useful trophic function, supporting cellular proliferation and activity in multiple tissues, including the HIP, not only hematopoietic tissue. The higher levels of TFRC and ALAS1 in baseline iP rats are consistent with the emerging picture of them being more robust and active. Similarly, selection for high alcohol preference in other rat lines have produced rats that have a greater survival rate, lower rates of kidney disease, benign tumors and cardiovascular disease than rats selected for low alcohol preference. 93 Additionally, a lifetime of alcohol consumption slightly increased the lifespan of Alko, Alcohol (AA) rats. 93 Thus, the increase in TFRC and ALAS1 in response to alcohol may be, at least initially, a tonic, and might underlie some of the health benefits in humans of intermittent use of low to moderated doses of alcohol. 94 Cardiovascular regulation and alcoholism Among our top candidate genes (Figure 3) , we have two genes that are known to be involved in cardiovascular regulation, PRKCE and AGT. Excessive alcohol consumption has been associated with cardiovascular disorders, including Convergent functional genomics of alcoholism ZA Rodd et al cardiomyopathy, hypertension, coronary artery disease and stroke. However, recent evidence suggests that moderate alcohol intake may provide a measure of cardioprotection, especially against coronary disease and ischemia-reperfusion injury. 94 PRKCE is a calcium-independent, phospholipid-dependent, serine-and threonine-specific enzyme involved in signal transduction in a wide variety of tissues. PKC has previously been implicated by cell culture studies of the effects of alcohol. 95, 96 Mice lacking PRKCE consume less alcohol and show greater acute sensitivity to alcohol than do wild-type mice. 97 Moderate alcohol consumption induces cardiac protection by activating PRKCE. 58, 98 PRKCE was also identified as a candidate gene for alcoholism by a recent mouse model gene expression meta-analysis. 99 Our data show that alcohol-preferring rats have a lower baseline level of PRKCE than alcohol-non-preferring rats in the AMY. Additionally, our data show that those levels are increased by chronic alcohol ( Table 2 ). The lower levels of PRKCE in the alcohol-preferring rats, whereas puzzling in view of the above-mentioned mouse literature relating to intake, may have less to do with alcohol consumption regulation and more to do with greater regio-specific sensitivity to alcohol in the AMY of these rats, perhaps in terms of fear reduction. This is consistent with the emerging picture of baseline iP rats being more sensitive to the desirable effects of alcohol than iNP rats. The increase of PRKCE by alcohol may be a phenomenon of tolerance, and is consistent with potential favorable cardiovascular benefits of moderate alcohol intake, like in the case of AGT. PRKCE maps to a locus on 2p21 that has been linked to schizophrenia, 86 as well as has been shown to be regulated by the mood-stabilizing drug lithium, 100 which may provide some mechanistic explanation for clinical comorbidities, and supports the use of lithium for the treatment of human alcoholism, especially when comorbid bipolar mood disorder exists.
AGT is a precursor of angiotensin II, a key enzyme in the renin-angiotensin system (RAS), involved in blood pressure regulation and other processes. Pharmacological and genetic manipulations of the RAS have been found to alter the voluntary consumption of alcohol. [101] [102] [103] Specifically, transgenic rats that express an antisense RNA against AGT and consequently have reduced AGT and Ang II levels exclusively in the central nervous system consumed markedly less alcohol in comparison to their wild-type controls. Moreover, spirapril, an inhibitor of the angiotensin-converting enzyme (ACE), which passes the blood-brain barrier, did not influence alcohol consumption in the transgenic rats, but it significantly reduced alcohol intake in wild-type rats. 102 Consistent with this, our data show that alcohol-preferring rats have higher baseline levels of AGT than alcohol-nonpreferring rats in the prefrontal cortex (PFC). Additionally, our data show that those levels are decreased by chronic alcohol (Table 2) . Last but not least, a Pathways Assist analysis of the known direct interactions between our top candidate genes identified AGT as a key node in the interaction network, as depicted in Figure 4b . The higher levels of AGT may have a tonic effect on blood pressure in these alcohol-preferring animals, and their capability to respond to the environment. 104 This is consistent with the emerging picture of baseline iP rats being more robust and active. The lowering of AGT by alcohol is consistent with potential favorable cardiovascular benefits of moderate alcohol intake. AGT maps to a locus on 1q42.2 that has been linked to bipolar disorder, 67, 105 as well as schizophrenia. 57, 106 Last but not least, AGT gene expression was reported to be downregulated in the FC in post-mortem brains of human alcoholics. 107 ACE inhibition effectively reduced alcohol drinking in animals with elevated RAS activity and not at all in animals with suppressed RAS activity, indicating that initial levels of RAS activity may determine the speed and ability of ACE inhibition to attenuate alcohol intake. 103 The alcoholpreferring rats, which have higher levels of AGT than alcohol-non-preferring rats, should be susceptible to ACE inhibitors in terms of reducing their alcohol intake behavior. To test this hypothesis, we treated alcohol-preferring rats with the ACE inhibitor lisinopril, and measured alcohol intake.
Effects of daily administration of lisinopril on the acquisition of ethanol and saccharin consumption Daily administration of lisinopril suppressed the acquisition of ethanol (EtOH) drinking during the initial 7 days of exposure in alcohol-preferring rats ( Figure 5; top panel) . A repeated-measure analysis of variance (ANOVA) revealed that across the 10 initial days of EtOH exposure, there was a significant effect of drug treatment (F 3,27 ¼ 5.9; P ¼ 0.003), a significant effect of day (F 6,22 ¼ 2.6; P ¼ 0.04) and a nonsignificant day Â treatment interaction (F 18,72 ¼ 0.98; P ¼ 0.50). One-way ANOVAs were conducted on the initial ten 24-h periods following injection. The results indicated that there were significant differences between the groups during injection days 3-7 and the first post-injection day (Fs 3,27 43 
Additionally, administration of lisinopril in these rats did not significantly reduce concurrent water intake ( Figure 5 ; top panel inset). A repeated measure performed on water intake levels conducted on the 2 days before lisinopril testing and the 7 days of lisinopril administration revealed that there was a significant effect of drug treatment (F 3,27 ¼ 4.4; P ¼ 0.012), a significant effect of day (F 8,20 ¼ 6.9; Po0.0001) and a significant day Â treatment interaction (F 24,66 ¼ 2.4; P ¼ 0.002). Rats administered saline or 1 mg/kg lisinopril reduced water intake when EtOH was made available (indicating the preference for EtOH that the P rat was selected), whereas the rats administered 3 or 10 mg/kg lisinopril maintained their water intake levels. Administration of lisinopril did not alter body weight (Figure 1; bottom panel inset) . Comparable analysis revealed a significant effect of day (Po0.0001), which indicated that all rats put on weight, but no effect of drug treatment or a day Â treatment interaction (P-values 40.33).
Peripheral administration of lisinopril did not alter saccharin consumption in the alcohol-preferring rats ( Figure 5 ; bottom panel). There were no significant effects of drug treatment (P ¼ 0.45) or a drug treatment Â day interaction (P ¼ 0.23). In general, alcohol-preffering rats consumed a large quantity of saccharin (480 g/day), and this was not altered by lisinopril. Repeatedly, there was no alteration in body weight or water intake (water intake was greatly reduced in all groups with the introduction of saccharin) following lisinopril (P-values 40.56).
Cellular stress response and alcoholism MAPK14 responds to activation by environmental stress, proinflammatory cytokines and lipopolysaccharide by phosphorylating a number of transcription factors, such as ELK1 and ATF2, and several downstream kinases, such as MAPKAPK2 and MAPKAPK5. It plays a critical role in the production of some cytokines, for example, interkeukin-6. MAPK14 was also identified as a differentially expressed gene in carefully carried out microarray studies and analyses in alcohol-preferring AA (alko, alcohol) rats vs alcoholavoiding ANA (alko, non-alcohol) rats. 108, 109 Our data show that alcohol-preferring iP rats have a lower baseline level of MAPK14 than alcohol-non-preferring iNP rats in the CP. Additionally, our data show that those levels are increased by chronic alcohol (Table 2) . Last but not least, a Pathways Assist analysis of the known direct interactions between our top candidate genes identified MAPK14 as a key node in the interaction network, as depicted in Figure 4b . The lower levels of MAPK14 in alcohol-preferring rats may permit them to be associated with lower responsivity to alcohol-induced cellular stress changes, and thus presumably to the aversive effects of alcohol. As mentioned previously, iP rats are less susceptible to the motor-impairing effects of alcohol than iNP rats.
55 MAPK14 maps to a region on 6p21.31 that has been implicated in human linkage studies of alcoholism, 110 as well as schizophrenia. 111, 45 Moreover, MAPK14 has been shown to be upregulated in the PFC and NAC in post-mortem human brains from alcoholics. 27 Heat-shock 27 kDa protein 1 (HSPB1) is downstream of MAPK14 in the MAPK pathway, and is involved in stress resistance and actin organization. Mutations in HSPB1 are the cause of Charcot-Marie-Tooth disease type 2 and of distal hereditary motor neuropathy. Our data show that alcohol-preferring rats have a higher baseline level of HSPB1 than alcohol-non-preferring rats in the HIP. Additionally, our data show that those levels are increased by chronic alcohol ( Table 2 ). The higher levels of HSPB1 in alcohol-preferring rats may permit them to be more resilient to alcohol-induced cellular stress changes, and thus presumably to the aversive effects of alcohol. The increase in HSPB1 with chronic alcohol may be part of a hormesis-like neuroadaptation mechanism. HSPB1 levels have also been shown to be increased in post-mortem human brains from bipolar disorder and schizophrenia, 112 and as part of the reactive gliosis in Alzheimer disease. Cell proliferation and alcoholism Among our top candidate genes, we have at least three genes involved in cell proliferation: CCND1, FYN and IGFR1. Alcoholism is associated with an increased risk for cancers. Cyclin D1, FYN and IGF1R have key roles in promoting cell proliferation, and higher levels of them are observed in various tumors. [114] [115] [116] Our data show that alcohol-preferring rats have lower baseline levels of cyclin D1 than alcoholnon-preferring rats in the AMY, and these levels are increased by the chronic administration of alcohol (Table 2) . Cyclin D1 maps to a locus on 11q13.3 that has been linked to bipolar disorder 117 and schizophrenia. 118 Last but not least, cyclin D1 gene expression was reported to be altered in post-mortem brains of human alcoholics. 59 Our data also show that alcohol-preferring rats have lower baseline levels of FYN and IGF1R than alcohol-non-preferring rats in the NAC, and that these levels are decreased by the ICSA of alcohol in the VTA (Table 3 ). The lower baseline levels of cyclin D1, FYN and IGFR1 in iP rats suggests that they may be less susceptible to overreact with cell proliferation and develop cancers, whether due to alcohol or other environmental factors. This is consistent with a picture of physiological resilience in these alcoholpreferring animals.
Alcohol metabolism
Among our top candidate genes, we have three genes involved directly or indirectly in alcohol metabolism: ALDH1A1, aldehyde dehydrogenase 2 (ALDH2) on 12q24.1 and ALDH6A1 on 14q24.23. ALDH1A1 is an important enzyme in the metabolism of acetaldehyde and the synthesis of retinoic acid. It maps to a region on chromosome 9q21.12 that has been linked to alcoholism 107,119-121 and bipolar disorders. 67 Moreover, a recent study has shown association between ALDH1 promoter polymorphisms and alcohol-related phenotypes in southwest California Indians. 120 Moreover, there is evidence of decreases in ALDH1 levels in post-mortem brains of persons with 1, 3 , or 10 mg/kg) on the acquisition of 24-h free choice EtOH intake (15% v/v; top panel), concurrent water intake (top panel insert), saccharin intake (0.025%; bottom panel), and body weight in adult, male P rats (n ¼ 6-8/group). Lisinopril only affected the EtOH intake (top panel). Asterisks represent that rats administered 3 or 10 mg/kg lisinopril consumed significantly less EtOH than rats administered saline or 1 mg/kg lisinopril. Pound symbols indicate that rats administered 1, 3, or 10 mg/kg lisinopril consumed less EtOH than rats treated with saline.
Convergent functional genomics of alcoholism

ZA Rodd et al
schizophrenia. 122 Our data show that alcohol-preferring rats have higher baseline level of ALDH1A1 than alcohol-nonpreferring rats in the HIP, as well as the FC. Additionally, our data show that those levels are increased in the HIP in the ICSA alcohol administration paradigm also (Table 3) . ALDH1 may serve an important function in metabolizing the by-products of alcohol, and thus limiting its aversive effects. This is consistent with the iP rats being more resilient to the aversive effects of alcohol, and thus being able to ingest higher amounts. Similarly, ALDH2 alleles have been associated with inability to ingest large amounts of alcohol and facial flushing in response to alcohol. 123 Our data show that alcohol-preferring rats have higher baseline level of ALDH2 than alcohol-non-preferring rats in the NAC. Additionally, our data show that those levels are increased in the AMY in the ICSA alcohol administration paradigm (Table 5) . Last but not least, ALDH6A1, which maps to a region on 14q24.23 implicated in alcoholism, 110 was changed in the CP in all the three paradigms included in our analysis (Table 1) . 124 SYN2 is decreased in the CP of iP vs iNP rats, and expression is increased by the ICSA administration of alcohol (Table 3) . SYN2 maps to a locus on chromosome 3p25.2 that has been implicated in schizophrenia. 57, 125 There is evidence of downregulation in post-mortem brain tissue of persons with schizophrenia and bipolar illness, 126, 127 as well as in persons with alcohol dependence. 59, 128 Our findings of lower SYN2 in iP rats, and its increase by alcohol administration, suggest that iP rats, and by extension human alcoholics, may be using alcohol to improve a baseline cognitive deficit.
BDNF promotes the survival of neuronal populations in the CNS. BDNF has been implicated in substance abuse, 129 alcoholism 130, 131 and depression. 132 In our data sets, we see BDNF increased in the AMY in both the iP rats vs iNP rats paradigm, and in the ICSA administration of alcohol paradigm (Table 3) . These findings are intriguing, and are consistent with the physiological robustness of the iP rats, and perhaps a positive effect of the stress of exposure to alcohol (hormesis). BDNF maps to a locus on chromosome 11p14.1 that has been implicated in human genetic studies of alcoholism, 133 bipolar affective disorder [134] [135] [136] [137] [138] and schizophrenia. 139 There is post-mortem human brain evidence regarding its downregulation in bipolar, 140 suicide, 141 schizophrenia 142 and Alzheimer disease. 143 Our findings of increased BDNF are intriguing. They contrast with the decrease in human post-mortem data, and are consistent with the physiological robustness of the iP rats, perhaps positive effects of the stress of exposure to alcohol (hormesis) and elevated mood.
GNAS is involved in hormonal regulation of adenylate cyclase. It activates the cyclase in response to betaadrenergic stimuli. GNAS has been implicated in both alcoholism 144 and anxiety. 145 In our data sets, GNAS is decreased in the AMY in both the iP rats vs iNP rats paradigm, and in the chronic alcohol administration paradigm (Table 2) . GNAS maps to a locus on chromosome 20q13.32 that has been implicated in low level of response to alcohol. 119 Our findings of lower GNAS in iP rats in the AMY suggest a decreased reactivity to fearful stimuli. The decrease of GNAS induced by chronic alcohol may underlie some of the anxiolytic effects of alcohol.
TH, mainly expressed in the brain and adrenal glands, is the rate-limiting enzyme in the biosynthesis of catecholamines. TH has been suggested to be implicated in both bipolar disorder and alcoholism by earlier human genetic studies, 146, 147 although the evidence published since has been contradictory. In our data sets, we see TH decreased in the CP of iP rats vs iNP rats, and also decreased in the HIP by chronic alcohol (Table 5) . TH maps to a locus on chromosome 11p15.5 that has been implicated in human genetic studies of alcoholism, bipolar disorder and schizophrenia. There is biological evidence of its involvement in alcohol abuse, anxiety and suicidality, including changes in post-mortem human brains (decreased in the FC of alcoholics 88 and in the locus coeruleus of suicide victims 148 ). Our findings of lower TH in iP rats, and its decrease by alcohol administration, may fit together into a picture of impulsivity and poor behavioral control.
Taken together, the data for SYN2, BDNF, GNAS and TH point to a picture of decreased cognition, physiological robustness, elevated mood, decreased anxiety, low response to alcohol and impulsivity in the male iP rats, and by extrapolation, alcohol-preferring men. This is not dissimilar to type B alcoholism, 149 or indeed anti-social personality disorder, and hyperthymic temperament, 150 as we go in our translational comparison from DSM-IV axis I (psychiatric disorders), to axis II (personality disorders), to normal population variants (temperaments).
GeneSpring clustering analysis of top candidate genes (Figure 3c)
Unsupervised hierarchical clustering of the top candidate genes in the pyramid using GeneSpring revealed, first, that the two alcohol treatment paradigms (Paradigms 2 and 3) cluster more closely together than with the baseline iP vs iNP strain comparison (Paradigm 1). This is reassuring, as it indicates a distinguishable effect of alcohol administration in two very different paradigms. Second, the analysis revealed two major clusters of genes that show a reciprocal relationship of increase (I) and decrease (D) in Paradigm 1 (iP vs iNP) and Paradigm 3 (ICSA alcohol), with no overall marked effect (N) in the chronic alcohol treatment (Paradigm 2). The lower cluster, containing genes that are predominantly lower in iP rats, involves genes that may have to do with mediating the aversive effects of alcohol (FN1, MAPK14, PRKCE, ALDH6A1), and the upper cluster, containing genes that are predominantly higher in iP rats, involves genes that may have to do with physiological resilience and rewarding effects of alcohol (VCAM1, CD81, TFRC, LYZ, ALDH1A1, AGT, CAMKK1 (Ca 2 þ /calmodulindependent protein kinase 1, alpha), GNAS). This is consistent with the emerging overall picture of physical and physiological robustness, tolerance and increased reward in the alcohol-preferring male rats, and by extension, male alcoholics, somewhat evocative of the 'Irishman stereotype'. [151] [152] [153] GeneOntology analysis of results GeneOntology (GO) analysis of the complete data set, Categories I and II (Table 6a ), revealed that the highest probability genes were genes having to do with cellular processes (1, 3) , infrastructure (4, 5) and response to external (2) . This is consistent with a model of alcohol abuse disorders that might be speculated to involve a reaction to external stimuli in the form of modified cellular functions, and infrastructure changes/tissue re-modeling (Figure 4b ). Of note, a GO analysis of only the top candidate genes revealed a similar distribution of cellular functions (1, 7) and response to stimulus (4) ( Table 6b and Figure 4b ). Our approach described so far is to generate data in an appropriate discovery paradigm and let the data coalesce into possible mechanistic interpretations. An opposite, hypothesis-driven approach for mining our data sets is to ask whether genes related to known biological mechanisms of interest (Table 7) , linkage loci (Table 1S -see Supplementary material) or post-mortem findings (Table 8) are present in them -spanning the spectrum from the more sensitive (biological) to the more specific (post-mortem) external corroborative lines of evidence.
Biological roles
An interrogation of our complete data set of reproducibly changed genes, Categories I-III, for classification into functional groups that have been previously implicated or hypothesized to have relevance to the pathophysiology of alcoholism and related disorders, yielded genes related to neurotransmission (GABA, dopamine, acetylcholine, adenosine), cellular mechanisms (cell adhesion signaling, cellular stress response, clock genes, transporters, synaptic function) and physiological functions (alcohol metabolism, lipid metabolism, iron metabolism, growth factors) ( Table 7) .
Cross-validation with human linkage loci
An interrogation of our data set for genes that map to the linkage loci for alcoholism, as well as loci for bipolar disorder and schizophrenia, yielded a series of candidate genes at those loci (Table 1S -see Supplementary material) , which may help prioritize future candidate gene research for each of these loci.
Cross-validation of human post-mortem findings Last but not least, an interrogation of our data set with genes that have previously been reported in the literature to be altered in post-mortem brains from subjects with alcoholism, as well as post-mortem brains from subjects with other neuropsychiatric disorders (bipolar, schizophrenia, dementia, depression, suicide), confirmed in our data set some of those earlier findings (Table 8) . This cross-validation, on the one hand, reinforces the validity of our approach and, on the other hand, reduces the likelihood that those particular post-mortem findings are methodological or gene-environment interactions artifacts of work with post-mortem human tissue. Moreover, it illustrates at a genetic and neurobiological mechanism level the overlap among major neuropsychiatric disorders. 154 
Discussion
With the goal of helping break the genetic code of alcoholism, we have used a comprehensive translational approach for identifying high-probability candidate genes, pathways and mechanisms for alcoholism, by integrating in a Bayesian fashion multiple independent lines of evidence. The analysis revealed that alcohol has pleiotropic effects on multiple systems, with a consequent wide anatomical and physiological impact, which may explain the diverse neuropsychiatric and medical pathology in alcoholism.
Limitations and confounds
Inbred rat lines, such as those used to generate the data analyzed in this paper, are prone to accumulating genetic defects that may be reflected in gene expression levels. While we have no way of knowing if some of the genes we captured in our screen are the result of such random accumulated defects rather than being involved in the preference or response to alcohol, it is to be noted that we have used three very different animal model paradigms in our analysis (alcohol preference selection, response to chronic oral alcohol and response to the ICSA of alcohol in the VTA), focusing on genes that are changed in common among these different paradigms rather than genes that are unique to one paradigm or another. It is to be noted that some of these gene changes have also been reported in post-mortem brains of alcoholic patients or patients with other neuropsychiatric disorders (Table 8 ). Moreover, we have candidate genes in our data set that are involved in pathways known from previous work to be associated with alcohol response (such as GABA genes), or with alcohol metabolism (such as aldehyde dehydrogenase genes) ( Table  7) . More work, in transgenic mouse models, for example, should nevertheless be pursued to establish unambiguously the roles of our top candidate gene findings in the neurobiology of response to alcohol.
Different combinations of alcohol animal models, treatments and comparisons others than the ones we have used could be integrated in a comprehensive approach such as the one we have described. They could conceivably lead to different results, which would be of interest and quite useful, as it is unlikely that we are capturing with the models that we have used the full spectrum of gene expression changes and mechanisms involved in alcoholism. However, if those other models indeed mimic and modulate the same core phenomenology, the Venn diagram of overlaps between different experimental paradigms will be of high utility and interest in terms of identifying the key molecular players involved in the effects, as opposed to those involved in the (very different) artifacts of the different individual experimental models. Along these lines, microarray studies in microdissected brain regions of alcohol-preferring AA (alko, alcohol) rats vs alcohol-avoiding ANA (alko, nonalcohol) rats 108, 109 have identified some of the same genes identified in our data set: MAPK14, microtubule-associated protein tau (MAPT), KCNA4 (potassium channel voltagegated, shaker-related subfamily, member 4), GABRD (gamma-aminobutyric acid receptor, delta), ADORA2A (adenosine A2a receptor), THRA and RB1. Of note, an elegant meta-analysis of mouse alcoholism models was reported recently. 99 We do not see a significant overlap between our results and the top results of that analysis, with the exception of PRKCE, CRYAB and NICN1. It has to be pointed, however, that the design of their study was different than ours and had two major potential limitations:
(1) the use of whole-brain gene expression data, which could confound signal from specific brain regions; (2) the crossmatching of their results to congenic mouse strain data instead of human genetic and post-mortem data, which arguably reduces the specificity and relevance of their findings for the human condition purported to be modeled. Our experimental approach for detecting gene expression changes relies on a single methodology, Affymetrix GeneChip microarrays. It is possible, indeed likely, that at least some of the gene expression changes detected from a single biological experiment, with a one-time assay with this technology, are technical or biological artifacts. Cognizant of that, we have designed our analysis to minimize the likelihood of having false positives, even at the expense of having false negatives. Our approach, as described above, based on the same genes being changed across different paradigms, ensures some measure of biological and technical reproducibility, as the different paradigm animal experiments and microarray assays are carried out at different times. Moreover, it is weighted toward genes that are being changed in multiple paradigms in the same brain region, and less weighted toward genes that are changed in different brain regions in different paradigms. Finally, the external convergences, with human genetic linkage data, postmortem brain data and biological roles data, all serve to create a hierarchy in our findings that puts at the top genes with a reduced likelihood of type I error.
Our animal model data was generated from inbred male rats, and we may arguably miss gender-related differences in the underlying neurobiology of alcoholism. As such, our speculative translational conclusions below should be viewed with this major caveat in mind, and might be more germane to type II (or type B) alcoholism, which has a male preponderance, rather than to type I (or type A alcoholism).
We have performed our convergent analysis at an individual gene level, rather than a pathway level. As such, we may be missing many things. Arguably, pathways are more conserved than individual genes. 24 It may be worthwhile, with the emerging availability of more sophisticated bioinformatics approaches, to re-examine our data sets by doing convergence at a pathway rather than individual gene level. Another higher order analysis that needs to be carried out is that of epistasis, based on the possibility that 'genes that change together (may) work together'. 21, 23 Candidate genes need to be further validated by studying the phenotype of transgenic mice in which the gene of interest is ablated (knockout, small interfering RNA), or overexpressed. More definitive proof will consist of demonstrating association of polymorphisms in the gene with the illness in human candidate gene association studies. The ultimate proof, of course, would be evidence that those polymorphisms have functional significance. 24 
Conclusions and future directions
The current data analysis includes examination of innate neurological differences in gene expression in two rats lines selected for divergent propensity to consume alcohol (Paradigm 1). The genetic difference between these rat lines should reflect, in part, the components that facilitate the acquisition and maintenance of alcohol consumption. Theoretically, iP rats should have genetic differences from iNP rats that correspond with an increase in the rewarding properties of alcohol, an increase in the tolerance to the negative consequences of consuming copious amounts of alcohol and perhaps genes that increase the propensity to consume fluids and/or substances. However, a single gene could possibly mediate all three proposed components. Examination of the genetic alterations produced by chronic alcohol consumption in iP rats (paradigm 2) should have provided a list of genes that are induced by alcohol consumption that regulate alcohol reward/tolerance and fluid consumption. Correspondence of genes between the chronic alcohol consumption (Paradigm 2) and innate differences studies (Paradigm 1) should indicate the genes that are involved in both the propensity to consume alcohol and maintenance of alcohol consumption. However, genes differentially expressed following chronic alcohol consumption but not observed during the innate analysis may be solely inducible genes that mediate the same biological processes. Changes in gene expression following ICSA of alcohol into the posterior VTA (Paradigm 3) should primarily be the result of the reinforcing actions of alcohol in this region. Therefore, convergent genetic alterations in The analysis revealed at the top of the list genes related to cell adhesion and signaling (FN1 on 2q35, VCAM1 on 1p21.2 and CD81 on 11p15.5), catecholamine biosynthesis (TH on 11p15.5), iron-heme metabolism (TFRC (transferin receptor mRNA) on 3q29 and ALAS1 on 3p21.2), cardiovascular regulation (AGT on 1q42.2 and PRKCE on 2p21), cellular stress response (MAPK14 on 6p21.31), cell proliferation and differentiation (cyclin D1 on 11q13.3, FYN on 6q21, IGFR1 on 15q26.3), nuclear pore function (NUPL1 on 13q12.13), anti-bacterial protection (LYZ on 12q15), Golgi/ endoplasmic reticulum function (STX12 on 1p35.3) and alcohol metabolism (ALDHA1 on 9q21.12, ALDH6A1 on 14q24.23 and ALDH2 on 12q24.1). Nine of these 17 genes map to genetic linkage loci for alcoholism, and eight out of these 17 genes have published evidence of human postmortem brain changes in alcoholism. These data reveal that alcohol has pleiotropic effects on multiple systems, with a consequent wide anatomical and physiological impact, which explains the diverse medical and neuropsychiatric pathology in alcoholism. More specifically for the latter, among the top candidate genes we have genes related to schizophrenia (SYN2 on 3p25.2 and APOD on 3q26.2-qter), bipolar disorders (BDNF on 11p14.1), anxiety (GNAS on 20q13.32 and NR3C1 on 5q31.3) or all three (TH on 11p15.5), as well as neurite outgrowth (NRN1 on 6p25.1) and myelin formation (PBP on 12q24.23). Moreover, 20 of the 24 genes mentioned above map to genetic linkage loci previously implicated in bipolar disorder and/or schizophrenia, and seven out of these 24 genes have published evidence of human post-mortem brain changes in bipolar and/or schizophrenia. These data may explain why alcohol abuse can lead to mood, psychotic and anxiety symptoms, and have permanent deleterious effects on brain infrastructure. In addition, other candidate genes (involved in response to external stimuli, cellular physiological processes, metabolism and infrastructure), pathways and mechanisms of likely importance in pathophysiology were identified from the complete data sets.
The results presented in this paper have a series of direct implications. First, in terms of pharmacotherapy and drug development, some of the candidate genes in our data sets encode for proteins that are modulated by existing pharmacological agents (Table 9) , which may suggest future avenues for rational polypharmacy using existing agents. Such existing, non-addictive drugs include, for example, ACE inhibitors for the AGT pathway, and mood-stabilizing drugs (lithium for PRKCE, lamotrigene and zonisamide for SCN1A, olanzapine for GABRA1 (gamma-aminobutyric acid receptor, alpha 1)). Moreover, our data sets of the effects of alcohol on gene expression in different key brain regions (Tables 1-5) , as well as the pathways and mechanisms identified, may be of use as a source of new targets for drug development. We have pursued one of this leads, modulating the AGT pathway with the ACE inhibitor lisinopril, and showed significant reduction in alcohol consumption in iP rats ( Figure 5 ). Given the high comorbidity of alcoholism and hypertension, the original medical condition for which ACE inhibitors have been approved and marketed, human Candidate genes in our data set that have also been reported in human post-mortem brain studies of alcoholism and other neuropsychiatric disorders.
Convergent functional genomics of alcoholism ZA Rodd et al clinical trials in alcohol-abusing subjects with comorbid hypertension are warranted, and satisfy the Hippocratic principle of primum non nocere (first do no harm). Second is the uncovered relationship between brain genes involved in alcohol response and cell adhesion signaling processes. The research literature has long contained references to cell adhesion molecules, not only in relationship to alcohol but also for other drugs of abuse. It seems possible that nature, given the limited repertoire of genes and proteins, has recruited more primitive mechanisms related to cell adhesion signaling for higher functions such as neuropsychiatric processes involved in addiction. The utility of regulating cell adhesion processes in response to alcohol abuse is of speculative evolutionary interest, and of pragmatic clinical importance. Speculatively, the emergent overall picture is that physical and physiological robustness may permit alcohol-preferring individuals to withstand the aversive effects of alcohol, which is essentially an organic solvent. In conjunction with a higher reactivity to its rewarding effects, they may able to ingest enough of this nonspecific drug for a strong hedonic and addictive effect to occur. Pragmatically, it underscores the profound physicophysiological impact of alcohol abuse, the potential prenatal teratogenicity and postnatal cumulative end-organ damage, and points to the importance of prevention and abstinence in the treatment of alcoholism. Third, the model that emerges out of the GO analysis of our data is that of environmental input leading to changes in cellular function and infrastructure changes (Figure 4b ).
The simplicity of the model should not eclipse the important fact that it is the result of empirical coalescence of data in a non-hypothesis-driven, discovery-type approach. Moreover, the implications for understanding the pathophysiology and treatment of alcohol disorders are profound. One needs to modulate environmental input, internal cellular functions and infrastructure changes in the treatment of these disorders. It is a place where both pharmacology and cognitive-behavioral psychotherapeutic interventions can and should go hand in hand.
Fourth, the identification of candidate genes for alcoholism that have also been implicated in other neuropsychiatric disorders, such as schizophrenia, bipolar disorder and anxiety may explain the comorbidity between alcohol abuse, psychosis and affective disorders. Whether the initial entry point into pathology is an underlying neuropsychiatric disorder with subsequent alcohol abuse, or whether alcohol abuse leads to neuropsychiatric symptoms, the genes and pathways identified may provide an opportunity to understand, and ultimately treat, these relatively refractory dual-diagnosis disorder patients.
In conclusion, we propose that our comprehensive translational CFG analysis of microarray data derived from various experimental paradigms in an established rodent model of alcoholism has produced novel candidate genes, pathways and mechanisms that could be of important heuristic value in the understanding of the biological basis of alcoholism, and the development of pharmacotherapies for the treatment of alcoholism. It arguably generates a series of immediate leads for both future research and clinical practice.
Materials and methods
Alcohol-naïve iP and iNP rats Most rodents do not voluntarily consume alcohol in sufficient quantities to produce pharmacologically meaningful blood alcohol levels. Through selective breeding, however, it has been possible to produce rats with either high (alcohol-preferring or P) or low (alcohol-non-preferring or NP) alcohol-drinking characteristics. [155] [156] [157] The P line of rats has been well characterized and meets the criteria for an animal model of alcoholism. The P line of rat prefers an EtOH solution over water at least at 2:1 ratio, whereas the NP rats show a preference ratio of less than 0.5:1. These rat lines also demonstrate distinct physiological and behavioral phenotypes in response to alcohol. 157, 158 Alcohol-naïve, male iP and iNP rats, 90-100 days old, were housed and killed as described previously. 29 Chronic alcohol vs water in iP rats Experimentally naïve, male iP rats (n ¼ 6 per group; iP 5c strain) from the 34th and 35th inbred generations, 4-6 months of age at the start of the experiment, were used as subjects. Food and water were available ad libitum throughout the experiments. Rats were given continuous free-choice access in the home cage to 15% (v/v) EtOH and water (alcohol group) or water only. Alcohol intake was relatively constant throughout the experiment (ranging from 5.8 to 6.4 g/kg/day). Samples were collected after the 10th week of alcohol access.
Intracranial self-administration of alcohol into the posterior VTA in iP rats Our third paradigm focuses on the neurocircuitry involved in alcohol reinforcement, and its gene expression response to alcohol. 30 The ICSA technique has been employed to identify specific brain regions involved in the initiation of response-contingent behaviors for the delivery of a reinforcer. 159, 160 Studies utilizing the ICSA procedure have successfully isolated discrete brain regions where opioids, 161, 162 amphetamine 163 and cocaine 164 may produce their rewarding effects. Recently, we have reported that alcohol is selfadministered into the posterior, but not anterior, VTA of Wistar and P rats, 30, 165 that P rats are more sensitive to the reinforcing properties of alcohol in the posterior VTA than Wistar rats 30 and that previous experience with oral alcohol consumption can significantly alter alcohol self-administration into the posterior VTA in P rats. 30 Additionally, microinjection of alcohol into the posterior VTA increases the amount of extracellular dopamine in the NAC shell. 166 Experimentally naïve, male iP rats were used. Rats were randomly assigned to one of two groups (n ¼ 4-5/group). A vehicle group received infusions of aCSF for eight sessions, each 4 h in duration, occurring every other day. The other group received infusions of 150 mg % alcohol for eight Convergent functional genomics of alcoholism ZA Rodd et al sessions. Immediately after the 8th session, rats were killed by decapitation. 30 
ACE inhibitor (lisinopril) experiments
Experimentally naïve, male alcohol-preferring P rats from the 60th and 61st selected generations, 4-6 months of age at the start of the experiment, were used as subjects. Rats were individually housed in hanging metal cages and allowed to acclimate to room and housing conditions for 6 days before any experimental manipulations. The room was maintained on a reverse 12L/12D hour cycle with lights on at 2100 hours. Before the acclimation period, all rats were handled at least seven times. During handling, the napes of the rats' necks were gently pinched to habituate the animal to the injection procedure. Food and water were available ad libitum thoughout the experiments.
Groups were matched for water intake and body weight during the acclimation period. Thirty minutes before the introduction of EtOH (15% (v/v)), separate groups of P rats received intraperitoneal (i.p.) injections of 0, 1, 3 or 10 mg/ kg lisinopril (n ¼ 7-8/group). For 7 consecutive days, rats received the same treatment at approximately 1200 hours. Rats were then allowed 20 days of continuous access to 15% EtOH. In the saccharin experiment, rats were treated identical to the EtOH acquisition study, except that 0.025% saccharin was concurrently available with water. Similarly, rats received 7 daily administration of lisinopril (0, 1, 3 or 10 mg/kg; n ¼ 5-6/group) followed by 20 days of continuous access to saccharin. The left-right positions of the two bottles were randomly switched each day. Fluid intake was recorded to the nearest 0.01 g by weighing the water and 15% EtOH bottles before and after each 24-h period. Body weights were also recorded every day for the duration of the injection phase. Fluid intake measures were converted into g EtOH/kg body weight (g/kg) and amount of water consumed (ml/day).
Data analysis consisted of a group Â day mixed ANOVA with repeated measures on 'day'. Dependent variables were 24-h EtOH (g/kg), water intake, body weight, and EtOH preference.
Microarray analysis
Tissues were dissected, and RNA was extracted and analyzed using standard Affymetrix GeneChip protocols, as described previously. 29 Each GeneChip was scanned and analyzed using Affymetrix Microarray Analysis Suite version 5.0 (Affymetrix: Affymetrix Microarray Suite User's Guide, version 5.0, Santa Clara, CA, USA; Affymetrix; 2001). Each sample was scaled to a target intensity of 1000 using the 'all probeset' scaling option; this option scales the trimmed mean target intensity to the specified value. For each probeset, absolute analysis generates a signal value (expression level), a detection call of 'absent', 'present' or 'marginal' and a P-value associated with the detection call. To reduce false positives from genes that were not reliably detected, the data wwere pre-filtered by only analyzing genes that were called 'present' in at least half of the arrays in at least one of the groups. This is a conservative way to remove from further analyses most genes that were not reliably detected in either group, while retaining those detected in at least one of the groups. 167 This filtering reduces the number of comparisons and of false positives, because genes not reliably detected exhibit high levels of noise. 167 For analyses, we compared the log 2 of the level of gene expression (signal) using Welch's approximate t-test, assuming unequal variance. This is a conservative test that we selected based upon our evaluation of the variances in many different microarray experiments. The log-transformed signal data more closely approximated a normal distribution than did the signal data. The transformation did not greatly affect the analyses. Nearly all of the genes that significantly differed would have been identified by analyses of untransformed data. We truncated the significance level, so that any P-value below 0.000005 is listed as 0.000000.
Gene identification
The identities of transcripts were established using NetAFFX (Affymetrix, Santa Clara, CA, USA), and confirmed by cross-checking the target mRNA sequences that had been used for probe design in the Affymetrix RGU34A GeneChip with the GenBank database. Where possible, identities of expressed sequence tags (ESTs) were established by BLAST searches of the nucleotide database. A National Center for Biotechnology Information (Bethesda, MD, USA) BLAST analysis of the accession number of each probeset was carried out to identify each gene name. BLAST analysis identified the closest known rat gene existing in the database (the highest known rat gene at the top of the BLAST list of homologs), which then could be used to search the GeneCards database (Weizmann Institute, Rehovot, Israel) to identify the human homolog. Probesets that did not have a known gene were labeled 'EST' and their accession numbers kept as identifiers.
Genetic linkage convergence
To designate convergence for a particular gene, the gene had to map within 10 cM of a microsatellite marker for which at least one published study showed evidence for linkage to alcoholism, or another neuropsychiatric disorder. The University of Southampton's sequence-based integrated map of the human genome (The Genetic Epidemiological Group, Human Genetics Division, University of Southampton, UK: http://cedar.genetics.soton.ac.uk/public_html/) was used to obtain cM locations for both genes and markers. The sex-averaged cM value was calculated and used to determine convergence to a particular marker. For markers that were not present in the Southampton database, the Marshfield database (Center for Medical Genetics, Marshfield, WI, USA: http://research.marshfieldclinic. org/genetics) was used to evaluate linkage convergence. Further information on specific gene function and biology was taken from the Online Mendelian Inheritance of Man database (http://ncbi.nlm.nih.gov/entrez/query. fcgi?db ¼ OMIM).
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Biological and tissue (post-mortem brain, lymphocytes) convergence Information about our candidate genes was obtained using GeneCards, as well as database searches using PubMed (http://ncbi.nlm.nih.gov/PubMed) and various combinations of keywords (gene name, alcohol, alcoholism, bipolar, schizophrenia, depression, suicide, dementia, opiates, cocaine, marijuana, hallucinogens, amphetamines, benzodiazepines, human, brain, post-mortem, lymphocytes, fibroblasts). Genes were deemed to have biological convergence if their known biological function was relevant to the pathophysiology of alcoholism and/or related disorders in human or animal models. Tissue convergence was deemed to occur for a gene if there were published reports of human post-mortem brain data (or, rarely, lymphocytes and other tissue data) showing changes in expression of that gene in tissue from patients with alcoholism and/or another neuropsychiatric disorder.
GeneSpring analysis
GeneSpring version 7.2 was used (Agilent Technologies, Palo Alto, CA, USA). Unsupervised two-way hierarchical clustering of gene expression fold-change data of the top candidate genes (from Figure 3a) was carried out.
GO analysis
The NetAffx Gene Ontology Mining Tool (Affymetrix, Santa Clara, CA, USA) was employed to categorize the genes in our data sets into functional categories, using the Biological Process ontology branch.
Pathway assist analysis
The Pathway Assist Version 3.0 Tool (Stratagene, San Diego, CA, USA) was employed to analyze the direct interactions (expression, regulation, transport, binding) of the top candidate genes resulting from our CFG analysis.
Ingenuity analysis
Ingenuity Pathway Analysis 3.0 (Ingenuity Systems, Redwood City, CA, USA) was employed to identify genes in our data sets that are the target of existing drugs.
